MiRNA Let-7a and Let-7d Are Induced by Globotriaosylceramide via NF-kB Activation in Fabry Disease

Background: Fabry disease is a hereditary genetic defect resulting in reduced activity of the enzyme alpha-galactosidase-A and the accumulation of globotriaosylceramide (Gb3) in body fluids and cells. Gb3 accumulation was especially reported for the vascular endothelium in several organs. Methods: Three Fabry disease patients were screened using a micro-RNA screen. An in vitro approach in human endothelial cells was used to determine miRNA regulation by Gb3. Results: In a micro-RNA screen of three Fabry patients undergoing enzyme replacement therapy, we found that miRNAs let-7a and let-7d were significantly increased after therapy. We demonstrate in vitro in endothelial cells that Gb3 induced activation of NF-kappa B and activated downstream targets. In addition, NF-kappa B activity directly reduced let-7a and let-7d miRNA expression as inhibiting NF-kappa B nuclear entry abolished the Gb3 effects. Conclusion: We suggest that let-7a and let-7d are potential markers for enzyme activity and inflammation in Fabry disease patients.

Automated summary

The study found that let-7a and let-7d miRNAs significantly increased in Fabry disease patients after enzyme replacement therapy, suggesting their potential as markers for enzyme activity and inflammation. Additionally, experimental results showed that Gb3 affects miRNA expression by activating NF-kappa B.